Track HEPA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Hepion Pharmaceuticals Inc
55 Madison Avenue, Morristown, NJ, United States, 07960
IPO
2014
Employees
2
Industry
Biotechnology
Sector
Healthcare
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20230+2
2
Q3 20230+4
4
2-quarter cumulative
0 sells6 buys
Analyst Ratings
1 analysts covering
Hold100%recommend hold
Buy
0
Hold
1
Sell
0